Free, research-backed cannabis education for adults 21+ Not medical advice · No product sales · For Clinicians

Research Summaries

In-depth, plain-language breakdowns of the three most important cannabis studies — what they found, what they missed, and what it means for you.

Thousands of cannabis studies are published every year, but most people do not have the time — or the scientific background — to read them. This page provides deep-dive summaries of three landmark studies that shape much of what we currently know about medicinal cannabis. For each study, we explain what the researchers set out to learn, what they found, what they did not find, the study's limitations, and what it all means for you as someone exploring cannabis for health purposes.

Why these three? These studies were selected because they are large-scale, peer-reviewed, recently published, and collectively cover the most common reasons people turn to medicinal cannabis: general therapeutic use, chronic pain, and anxiety. Together, they represent the best current snapshot of where the science stands.

1. The 2025 JAMA/UCLA Comprehensive Review

Full title: Comprehensive review of 2,500+ cannabis studies • Authors: Hsu et al. • Published: 2025, JAMA • Institution: UCLA Health

Strong Evidence

What They Studied

A team of researchers at UCLA Health undertook one of the most ambitious projects in cannabis research history: systematically reviewing more than 2,500 published studies on the therapeutic use of cannabis and cannabinoids. The review spanned a wide range of medical conditions, including chronic pain, nausea, epilepsy, anxiety, PTSD, sleep disorders, and many others. The goal was to assess the strength of available evidence for each condition and provide a clear picture of where the science actually stands — rather than where marketing claims suggest it stands.

What They Found

The findings were nuanced, which is itself an important takeaway:

  • Chronic pain: The strongest evidence exists for cannabis in the treatment of chronic pain. Multiple high-quality studies support a modest but meaningful reduction in pain, particularly neuropathic (nerve-related) pain. Products containing THC showed more consistent pain-relief effects than CBD-only products.
  • Chemotherapy-related nausea: There is solid evidence supporting the use of cannabinoids for nausea and vomiting associated with chemotherapy, a finding consistent with the fact that synthetic THC (dronabinol) has been FDA-approved for this purpose since the 1980s.
  • Epilepsy: Evidence supports CBD's effectiveness for certain severe seizure disorders, consistent with the FDA approval of Epidiolex.
  • Most other conditions: For the majority of conditions cannabis is commonly used for — including general anxiety, depression, PTSD, inflammatory bowel disease, and sleep disorders — the evidence was categorized as insufficient or inconclusive. This does not mean cannabis does not help; it means the rigorous studies have not been done.

What They Did Not Find

The review did not find strong evidence that cannabis is a broadly effective medicine for most of the conditions it is marketed for. It also did not find evidence that cannabis is a safe, risk-free substance — side effects including dizziness, cognitive impairment, and sedation were documented across many studies. Importantly, the review did not conclude that cannabis is ineffective for these conditions. The distinction between "insufficient evidence" and "evidence of ineffectiveness" is critical.

The absence of evidence is not evidence of absence. For many conditions, the studies simply have not been done at the scale and rigor needed to draw firm conclusions.

Hsu et al., JAMA (2025)

Limitations

  • Heterogeneity: The 2,500+ studies used wildly different methodologies, cannabis products, dosages, and outcome measures. Comparing them is like comparing apples to oranges to kiwis.
  • Short-term focus: Most included studies were short-term. Long-term safety and efficacy data remain scarce.
  • Product variability: Many studies used pharmaceutical-grade cannabis or isolated cannabinoids that do not reflect what patients actually buy at dispensaries.
  • Historical research restrictions: The review could only assess studies that exist. Decades of Schedule I classification meant many studies were never conducted in the first place.

What It Means for You

The bottom line: If you are considering cannabis for chronic pain or chemotherapy-related nausea, the evidence is on relatively solid ground. For other conditions, the science is still catching up. This does not mean cannabis will not help you — many patients report significant benefits for conditions where formal evidence is limited — but it does mean you should approach any claims of guaranteed effectiveness with healthy skepticism. Work with a knowledgeable healthcare provider who can help you weigh potential benefits against risks based on your specific situation.

2. The 2025 OHSU Living Review on Cannabis for Pain

Authors: OHSU Research Team • Published: 2025, Annals of Internal Medicine • Institution: Oregon Health & Science University

Moderate Evidence

What They Studied

Researchers at Oregon Health & Science University conducted what is known as a "living review" — a systematic review that is continuously updated as new evidence becomes available, rather than being a one-time snapshot. The focus was specifically on cannabis products for chronic pain in adults. The team evaluated different product types (inhaled, oral, topical), different cannabinoid compositions (THC-dominant, CBD-dominant, balanced), and different pain conditions (neuropathic pain, musculoskeletal pain, cancer-related pain, and others).

What They Found

  • THC-containing products showed a small but statistically significant reduction in pain across multiple pain conditions. The effect was modest — not a dramatic elimination of pain, but a meaningful improvement for many patients.
  • Higher THC content was associated with greater pain relief, but also with more side effects including dizziness, sedation, dry mouth, and cognitive impairment.
  • CBD-only products showed limited evidence of effectiveness for pain relief when used alone. This is an important finding given the widespread marketing of CBD products for pain.
  • Inhaled cannabis provided faster onset of pain relief compared to oral products, though effects were shorter-lasting.
  • Neuropathic pain (nerve pain) appeared to respond better to cannabis than other types of chronic pain.

What They Did Not Find

The review did not find evidence that cannabis is a superior alternative to established pain treatments for most patients. It did not find that CBD alone is an effective pain reliever at the doses commonly found in consumer products. It also did not find adequate long-term safety data — most included studies lasted weeks to a few months, not years.

Cannabis products with more THC slightly reduce pain but cause more side effects. The clinical significance of the pain reduction varied across studies and conditions.

OHSU, Annals of Internal Medicine (2025)

Limitations

  • Short study durations: Most included studies measured pain relief over weeks, not the months or years that chronic pain patients actually need treatment.
  • Placebo challenges: Cannabis is difficult to study with a true placebo because participants often know whether they received the active product (especially with THC, which produces noticeable psychoactive effects).
  • Product inconsistency: Studies used different products, doses, and administration methods, making direct comparisons difficult.
  • Side effect tradeoff: The products that worked best for pain also had the most side effects, creating a genuine tradeoff that each patient must weigh individually.

What It Means for You

The bottom line: If you are exploring cannabis for chronic pain, THC-containing products have more evidence behind them than CBD-only products. Start with low doses and increase gradually — the start low and go slow approach is especially important because the same higher doses that relieve more pain also cause more side effects. Be realistic in your expectations: cannabis may reduce your pain meaningfully, but it is unlikely to eliminate it entirely. And if you are currently on opioids or other pain medications, never make changes without your doctor's guidance.

3. The Johns Hopkins Anxiety Cohort Study

Authors: Wolinsky et al. • Published: 2025, Journal of Affective Disorders • Institution: Johns Hopkins University

Moderate Evidence

What They Studied

Researchers at Johns Hopkins University designed a cohort study to track adults who were using cannabis specifically for anxiety-related symptoms over an extended period. Unlike many previous studies that relied on one-time surveys or short observation windows, this study followed participants longitudinally, allowing researchers to observe how the relationship between cannabis use and anxiety symptoms evolved over time. The study measured standardized anxiety scores, frequency and type of cannabis use, dosing patterns, and overall quality of life.

What They Found

  • Sustained symptom reduction: The majority of participants reported meaningful reductions in anxiety symptoms that were sustained over the study period — not just a short-term honeymoon effect.
  • Dose matters: Consistent with the biphasic effect, participants who used lower doses reported better outcomes than those who used higher doses. This aligns with the foundational research by Rey et al. (2012) showing that low-dose THC tends to reduce anxiety while high-dose THC can increase it.
  • Not universal: A subset of participants experienced worsened anxiety, particularly those who used higher THC doses or who had a personal or family history of psychotic disorders.
  • CBD may help: Participants who used balanced THC:CBD products or CBD-dominant products reported fewer anxiety-worsening episodes than those using high-THC products alone.

What They Did Not Find

The study did not find that cannabis is universally effective for anxiety — a meaningful minority of participants did not benefit or got worse. It did not establish a clear optimal dose or product type for anxiety because individual variation was significant. It also could not determine causation: as a cohort study (not a randomized controlled trial), it can show strong associations but cannot definitively prove that cannabis caused the anxiety reductions observed.

Cannabis use for anxiety showed sustained benefits in the majority of participants, but a significant subset experienced worsened symptoms, underscoring the importance of individualized approaches and medical guidance.

Wolinsky et al., Journal of Affective Disorders (2025)

Limitations

  • Self-selection bias: Participants chose to use cannabis for anxiety. People who had bad experiences early may have dropped out, potentially skewing results toward positive outcomes.
  • Self-reported data: Anxiety measurements relied partly on self-reported questionnaires, which are inherently subjective.
  • No randomization: Without random assignment to cannabis vs. placebo groups, it is impossible to fully rule out the placebo effect or other confounding factors.
  • Product variability: Participants used a range of different cannabis products purchased from various dispensaries, making it difficult to isolate which specific products or formulations were most effective.

What It Means for You

The bottom line: If you are considering cannabis for anxiety, the Johns Hopkins study offers cautious encouragement — most participants saw real, lasting improvement. But the study also highlights genuine risks, especially at higher doses. The practical takeaway is clear: start with very low doses of a balanced or CBD-dominant product, increase gradually, and pay close attention to how you respond. If your anxiety worsens at any point, that is a signal to reduce your dose or stop. And if you have any history of psychotic disorders, talk to your psychiatrist before considering cannabis. For more on the biphasic effect and dosing, visit our Dosing Fundamentals page.

The Bigger Picture

Taken together, these three studies paint a consistent picture: cannabis shows genuine therapeutic promise, but it is not a miracle cure, and the evidence base is still developing. The honest answer to "does cannabis work?" is: it depends — on the condition, the product, the dose, and the individual.

What all three studies share is a call for more research. The evidence gap created by decades of Schedule I classification is slowly closing, but we are still years away from having the kind of comprehensive, long-term clinical data that exists for established pharmaceutical treatments.

In the meantime, the best approach is to be an informed, cautious consumer. Use the evidence that exists, acknowledge what we do not yet know, work with knowledgeable healthcare providers, and track your own experience carefully. For a complete list of the studies cited throughout this site, visit our Latest Studies page.